Investor Relations

Latest Financial Results

Q3 2022

Quarter Ended Sep 30, 2022

Latest Annual Filing

Fiscal Year Ended Dec 31, 2021

View Filing

Stock Information

Company Overview

Ocuphire Pharma is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders.

Download Ocuphire ZETA-1 Topline Results Conference Call Presentation

Investor Contact Information


Ocuphire Pharma, Inc.
37000 Grand River Ave., Suite 120
Farmington Hills, MI 48335
T: 248-681-9815
[email protected]

Investor Relations

LifeSci Advisors
250 West 55th Street, Suite 3401
New York, NY 10019
T: 646-889-1200
[email protected]

377 Oak Street, Level 2
Garden City, New York 11530
T: 212-655-0924
[email protected]

Transfer Agent

American Stock Transfer & Trust Company LLC
6201 15th Avenue
Brooklyn, NY 11219
T: 800-937-5449